ATTRUBY

Growth

acoramidis hydrochloride

BridgeBio Pharma
NDAORALTABLET
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100

Mechanism of Action

(TTR). Acoramidis binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers, the rate-limiting step in amyloidogenesis.

Indications (3)

the cardiomyopathy of wild-typevariant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular deathcardiovascular-related hospitalization

Loss of Exclusivity

LOE Date
Aug 16, 2039
163 months away
Patent Expiry
Aug 16, 2039
Exclusivity Expiry
Nov 22, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
10398681
May 5, 2031
Product
—
10842777
May 5, 2031
U-4046
8877795
May 5, 2031
Product
—
9169214
May 5, 2031
Product
U-4046
9642838
May 5, 2031
SubstanceProduct
—
Company
BridgeBio Pharma
BridgeBio Pharma
CA - Palo Alto
57 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers